1-(2-chlorophenyl)-1H-imidazole-5-carboxylic acid | 893615-79-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 1-(2-chlorophenyl)-1H-imidazole-5-carboxylic acid
• 英文别名: 3-(2-chlorophenyl)imidazole-4-carboxylic acid
• CAS: 893615-79-7
• 化学式: C₁₀H₇ClN₂O₂
• 分子量: 222.631
• InChiKey: VOPRHFSAKIIXGE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  55.1
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-(2-chlorophenyl)-1H-imidazole-5-carboxylic acid 、 5-[(4-氯苯氧基)甲基]-1,3,4-噻二唑-2-胺 在 N,N-二异丙基乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以23.7 %的产率得到N-(5-((4-chlorophenoxy)methyl)-1,3,4-thiadiazol-2-yl)-1-(2-chlorophenyl)-1H-imidazole-5-carboxamide
  参考文献：
  名称：

  [EN] NOVEL THIADIAZOLYL DERIVATIVES OF DNA POLYMERASE THETA INHIBITORS
  [FR] NOUVEAUX DÉRIVÉS DU TYPE THIADIAZOLYLE D'INHIBITEURS DE L'ADN POLYMÉRASE THÊTA

  摘要：

  Poly theta inhibitor (I), X is -N-or -C-; ring A is phenyl or a five to ten membered heteroaryl ring containing, inclusive of X, one to four heteroatoms independently selected from nitrogen, oxygen, or sulfur, Ar1 is phenyl, heteroaryl, heterocyclyl, bicyclic heterocyclyl, bridged heterocyclyl, or spiroheterocyclyl, wherein each of the aforementioned ring is substituted with Ra, Rb, and/or Rc,wherein Ra and Rb are independently selected from hydrogen, alkyl, halo, haloalkyl, alkoxy, haloalkoxy, cycloalkyloxy, acyl, acylamino, monoalkylamino, dialkylamino, alkylsulfonyl,cyano, and hydroxy; or Ra and Rb, when on adjacent ring vertices, combine to form a C3-6 cycloalkyl, or Ra and Rb, when on the same ring vertex, combine to form oxo, and Rc is selected from hydrogen, alkyl, halo, haloalkyl, alkoxy, haloalkoxy, hydroxy, hydroxyalkyl, alkoxyalkyl, aminoalkyl, heterocyclylalkyl, heterocyclyloxy, aminocarbonyl; Ar2 is phenyl, heteroaryl, or cycloalkyl, wherein said phenyl and heteroaryl are substituted with Rd, Re and/or Rf, wherein Rd and Re are independently selected from hydrogen, alkyl, halo, haloalkyl, alkoxy, haloalkoxy, hydroxy, and cyano and Rf is selected from hydrogen, alkyl, cycloalkyl, halo, haloalkyl, alkoxy, haloalkoxy, hydroxy, cyano, cyanomethyl, aminocarbonylmethyl, heteroaryl, and heterocyclyl, wherein said heteroaryl and heterocyclyl of Rf are unsubstituted or substituted with one, two, or three substituents independently selected from alkyl, halo, haloalkyl, and hydroxy; R1 is hydrogen, alkyl, halo, haloalkyl, haloalkoxy, alkoxy, hydroxy, cyano, cyanoalkyl,carboxy, alkoxycarbonyl, acylamino, aminocarbonyl optionally substituted heteroaryl, hydroxyalkyl, cycloalkyl, hydroxyalkynyl, alkoxyalkyl, aminoalkyl, aminocarbonylalkyl,sulfonylalkyl, aminosulfonylalkyl, optionally substituted heteroaralkyl, or optionally substituted heterocyclylalkyl; and R2 is hydrogen, alkyl, halo, haloalkyl, haloalkoxy, or cyano; Y is O or S or NH or NRg, Rg is a C1 to C3 aliphatic group; R3 and R4 are H, C1-6 aliphatic group.

  公开号：

  WO2023060573A1
• 作为产物：
  描述：

  ethyl 1-(2-chlorophenyl)-1H-imidazole-5-carboxylate 在 lithium hydroxide monohydrate 作用下， 以 甲醇 、 水 为溶剂， 生成 1-(2-chlorophenyl)-1H-imidazole-5-carboxylic acid
  参考文献：
  名称：

  [EN] NOVEL THIADIAZOLYL DERIVATIVES OF DNA POLYMERASE THETA INHIBITORS
  [FR] NOUVEAUX DÉRIVÉS DU TYPE THIADIAZOLYLE D'INHIBITEURS DE L'ADN POLYMÉRASE THÊTA

  摘要：

  Poly theta inhibitor (I), X is -N-or -C-; ring A is phenyl or a five to ten membered heteroaryl ring containing, inclusive of X, one to four heteroatoms independently selected from nitrogen, oxygen, or sulfur, Ar1 is phenyl, heteroaryl, heterocyclyl, bicyclic heterocyclyl, bridged heterocyclyl, or spiroheterocyclyl, wherein each of the aforementioned ring is substituted with Ra, Rb, and/or Rc,wherein Ra and Rb are independently selected from hydrogen, alkyl, halo, haloalkyl, alkoxy, haloalkoxy, cycloalkyloxy, acyl, acylamino, monoalkylamino, dialkylamino, alkylsulfonyl,cyano, and hydroxy; or Ra and Rb, when on adjacent ring vertices, combine to form a C3-6 cycloalkyl, or Ra and Rb, when on the same ring vertex, combine to form oxo, and Rc is selected from hydrogen, alkyl, halo, haloalkyl, alkoxy, haloalkoxy, hydroxy, hydroxyalkyl, alkoxyalkyl, aminoalkyl, heterocyclylalkyl, heterocyclyloxy, aminocarbonyl; Ar2 is phenyl, heteroaryl, or cycloalkyl, wherein said phenyl and heteroaryl are substituted with Rd, Re and/or Rf, wherein Rd and Re are independently selected from hydrogen, alkyl, halo, haloalkyl, alkoxy, haloalkoxy, hydroxy, and cyano and Rf is selected from hydrogen, alkyl, cycloalkyl, halo, haloalkyl, alkoxy, haloalkoxy, hydroxy, cyano, cyanomethyl, aminocarbonylmethyl, heteroaryl, and heterocyclyl, wherein said heteroaryl and heterocyclyl of Rf are unsubstituted or substituted with one, two, or three substituents independently selected from alkyl, halo, haloalkyl, and hydroxy; R1 is hydrogen, alkyl, halo, haloalkyl, haloalkoxy, alkoxy, hydroxy, cyano, cyanoalkyl,carboxy, alkoxycarbonyl, acylamino, aminocarbonyl optionally substituted heteroaryl, hydroxyalkyl, cycloalkyl, hydroxyalkynyl, alkoxyalkyl, aminoalkyl, aminocarbonylalkyl,sulfonylalkyl, aminosulfonylalkyl, optionally substituted heteroaralkyl, or optionally substituted heterocyclylalkyl; and R2 is hydrogen, alkyl, halo, haloalkyl, haloalkoxy, or cyano; Y is O or S or NH or NRg, Rg is a C1 to C3 aliphatic group; R3 and R4 are H, C1-6 aliphatic group.

  公开号：

  WO2023060573A1

文献信息

• [EN] THIADIAZOLYL DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS<br/>[FR] DÉRIVÉS DE THIADIAZOLYLE COMME INHIBITEURS DE L'ADN POLYMÉRASE THÊTA
  申请人：IDEAYA BIOSCIENCES INC

  公开号：WO2020243459A1

  公开（公告）日：2020-12-03

  Disclosed herein are certain thiadiazolyl derivatives Formula (I): that inhibit DNA Polymerase Theta (Polθ) activity, in particular inhibit Polθ activity by inhibiting ATP dependent helicase domain activity of Polθ. Also, disclosed are pharmaceutical compositions comprising such compounds and methods of treating and/or preventing diseases treatable by inhibition of Polθ such as cancer, including homologous recombination (HR) deficient cancers.

  本文披露了某些噻二唑基衍生物 Formula (I)：它们通过抑制 DNA 聚合酶 Θ（Polθ）活性来抑制 Polθ 活性，特别是通过抑制 Polθ 的 ATP 依赖螺旋酶结构域活性来抑制 Polθ 活性。此外，还披露了包括这些化合物的药物组合物以及治疗和/或预防通过抑制 Polθ 而可治疗的疾病的方法，如癌症，包括同源重组（HR）缺陷癌症。